anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Babies born with fetal growth restriction (FGR) are at higher risk of developing cardiometabolic diseases across the life course. The reduction in substrate supply to the developing fetus that causes FGR not only alters cardiac growth and structure but may have deleterious effects on metabolism and function. Using a sheep model of placental restriction to induce FGR, we investigated key cardiac metabolic and functional markers that may be altered in FGR. We also employed phase-contrast magnetic resonance imaging MRI to assess left ventricular cardiac output (LVCO) as a measure of cardiac function. We hypothesized that signalling molecules involved in cardiac fatty acid utilisation and contractility would be impaired by FGR and that this would have a negative impact on LVCO in the late gestation fetus. Key glucose (GLUT4 protein) and fatty acid (FATP, CD36 gene expression) substrate transporters were significantly reduced in the hearts of FGR fetuses. We also found reduced mitochondrial numbers as well as abundance of electron transport chain complexes (complexes II and IV). These data suggest that FGR diminishes metabolic and mitochondrial capacity in the fetal heart; however, alterations were not correlated with fetal LVCO. Overall, these data show that FGR alters fetal cardiac metabolism in late gestation. If sustained ex utero, this altered metabolic profile may contribute to poor cardiac outcomes in FGR-born individuals after birth. KEY POINTS: Around the time of birth, substrate utilisation in the fetal heart switches from carbohydrates to fatty acids. However, the effect of fetal growth restriction (FGR) on this switch, and thus the ability of the fetal heart to effectively metabolise fatty acids, is not fully understood. Using a sheep model of early onset FGR, we observed significant downregulation in mRNA expression of fatty acid receptors CD36 and FABP in the fetal heart. FGR fetuses also had significantly lower cardiac mitochondrial abundance than controls. There was a reduction in abundance of complexes II and IV within the electron transport chain of the FGR fetal heart, suggesting altered ATP production. This indicates reduced fatty acid metabolism and mitochondrial function in the heart of the FGR fetus, which may have detrimental long-term implications and contribute to increased risk of cardiovascular disease later in life.
Participants will receive RP2D of ASP1570 with some periodical drug holiday in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
INTRODUCTION: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA). The complications of JIA include pain, muscle weakness, limited movement and worsening quality of life. Yoga is an effective exercise therapy for rheumatoid arthritis and may have similar benefits for JIA. Considering the limitation of yoga for strengthening muscles, combined yoga and resistance training (CYRT) may compensate for the shortcomings and provide more benefits for JIA patients. Despite this, there is currently a lack of studies investigating the effectiveness of CYRT for JIA patients. Due to the inaccessibility of traditional exercise therapy, home-based exercise is needed. The study aims to assess the effectiveness of home-based CYRT on JIA.
METHODS AND ANALYSIS: This is a 12-week randomised single-blind controlled trial study. 60 patients with ERA will be randomised into two groups: the home-based exercise group (HBE) and the health education (HE) group. The HBE group (n=30) will perform the CYRT programme 3 times a week at home for 12 weeks and receive HE. The HE group (n=30) will only receive HE. The outcomes include primary outcome (pain levels) and secondary outcomes (lower limb muscle strength, motion range of joint, aerobic fitness, function ability, fatigue levels, mental health, quality of life and blood biomarkers). The assessments will be conducted at baseline, postintervention (12 weeks) and follow-up (24 weeks). Data will be analysed by intention to treat.
ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine in December 2023 (approval no. XHEC-C-2023-059-3). This study will require informed consent from all subjects and guardians of children under 18 years of age. The findings will be published in a peer-reviewed journal and international conferences.
TRIAL REGISTRATION NUMBER: ChiCTR2300073446.
The invention discloses an osteoporosis marker circRNA and application thereof, and belongs to the technical field of biology. The invention proves that the expression level of the circBBS9 and the human homolog thereof in osteoporosis is increased. Meanwhile, an siRNA capable of knocking down the expression of the circBBS9 is designed. The invention proves that miR-423-3p is a downstream target of the circBBS9. The expression of the circBBS9 in the polynucleation of the osteoclast is rapidly increased, and the inhibition of the circBBS9 does not influence the differentiation of the mononuclear precursor of the osteoclast, so that the polynucleation level and the bone resorption capacity of the osteoclast can be weakened, and the bone density of an osteoporosis mouse can be increased. This proves that the siRNA prepared by the invention can be applied as a medicament for preventing and treating osteoporosis.
It was demonstrated in BRAVO study that IVR had great effect for macular edema with BVO both in visual and anatomical outcome. However IVR was done monthly for all patients (except Sham group) during the first 6 months in BRAVO study. It is expected that similar results could be obtained by less frequent IVR, and if so, it will contribute to reduce patient's burden and medical cost. Thus it is necessary to determine the optimal regimen of IVR therapy.

In this study, considering the medical and social circumstances in Japan, the investigators are going to investigate if IVR by PRN is as effective as BRAVO study.In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area (NPA), because VEGF is thought to be released from non-perfused retinal tissue, and VEGF production may be correlated with NPA size and location. The investigators are going to measure the size of NPA semi-quantatively by ultra wide field fluorescein angiography (UWFA) using Optos 200Tx. Then the relationship with macular edema will be studied. The effect of ranibizumab to NPA is controversial. In this study, it will be investigated, too.
Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
An inhalable composition comprising: nicotine or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric alcohol : glycol or glycol ether by weight is from 6:1 to 1:1. An inhalable composition comprising: nicotine or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric alcohol : glycol or glycol ether by weight is from 6:1 to 1:1. A method of and apparatus for creating record data for an authorising body of, for example, skips and other waste containers is disclosed. Such a system includes receiving data from a telemetry system attached to a skip lorry. This data includes, vehicle identification data, location data identifying a location of the vehicle and loading/unloading data identifying when an object is loaded onto and/or unloaded from the vehicle. This data is then processed to determine locations where waste containers have been loaded and unloaded from vehicles and compare this to a permit booking system to ensure compliance with the booking system.
Cancer patients often experience anemia due to the disease itself, chemotherapy, or both. Quality of life is also affected, in part because of the fatigue associated with anemia. Previous studies with epoetin alfa have suggested that achieving a higher hemoglobin level may improve quality of life and help patients live longer. The primary objective of the study is to demonstrate the effectiveness and safety of epoetin alfa on the reduction in red blood cell transfusions needed in gastric and rectal cancer patients undergoing preoperative chemotherapy and radiation therapy (chemoradiation), followed by surgery. The purpose of this study is to assess the effectiveness of 40,000 to 60,000 Units of epoetin alfa or matching placebo injected under the skin once weekly for up to 16 weeks (starting 1 week before chemoradiation and extending up to 4 weeks after surgery) in reducing red blood cell transfusions during the 16-week period. Other effectiveness measures include the ability of epoetin alfa to maintain baseline hemoglobin levels during the chemoradiation and its effect on quality of life and tumor response during the study period. The safety of epoetin alfa will be assessed by incidence and severity of adverse events, clinical laboratory tests, physical examinations, and vital signs. The hypothesis of the study is that epoetin alfa is superior to placebo in reducing the number of transfusions, preventing anemia and improving quality of life during chemoradiation, surgery, and immediately after surgery. 40,000 to 60,000 Units of epoetin alfa or placebo injected under the skin once weekly for up to 16 weeks. First 4 weeks the dose is 40,000 Units; increased to 60,000 Units weekly starting at week 4 of chemoradiation if hemoglobin decreases by \>=1 g/dL and/or is \<=13 g/dL after 4 weeks of treatment.
PROBLEM TO BE SOLVED: To obtain a new dietary fiber composition capable of preventing unpleasant symptoms caused by water-soluble dietary fibers such as diarrhea and further increasing effects of the ingested water-soluble dietary fibers. SOLUTION: This new dietary fiber composition comprises a substance, separated from barley malts or rice germinated seeds and containing 10-70wt.% protein and 20-70wt.% insoluble dietary fibers and water-soluble dietary fibers (e.g. a polydextrose). The mixing weight ratio of the substance containing the protein and insoluble dietary fibers to the water-soluble dietary fibers is (5:1) to (1:3). The composition is capable of raising fecal discharging ability possessed by the water-soluble dietary fibers and simultaneously suppressing diarrhea which is an adverse effect of the water-soluble dietary fibers. A food and drink containing the composition is effectively used as a functional food having intestinal mucosal enhancing actions or defecation promoting actions.  The composition is useful as an intestinal mucosal enhancer, a defecation promoter and an agent for controlling the intestinal functions.
Diabetic vascular complications include diabetic macroangiopathy and diabetic microangiopathy. Diabetic microangiopathy is characterised by impaired microvascular endothelial function, basement membrane thickening, and microthrombosis, which may promote renal, ocular, cardiac, and peripheral system damage in diabetic patients. Therefore, new preventive and therapeutic strategies are urgently required. Sirt1, a member of the nicotinamide adenine dinucleotide-dependent histone deacetylase class III family, regulates different organ growth and development, oxidative stress, mitochondrial function, metabolism, inflammation, and aging. Sirt1 is downregulated in vascular injury and microangiopathy. Moreover, its expression and distribution in different organs correlate with age and play critical regulatory roles in oxidative stress and inflammation. This review introduces the background of diabetic microangiopathy and the main functions of Sirt1. Then, the relationship between Sirt1 and different diabetic microangiopathies and the regulatory roles mediated by different cells are described. Finally, we summarize the modulators that target Sirt1 to ameliorate diabetic microangiopathy as an essential preventive and therapeutic measure for diabetic microangiopathy. In conclusion, targeting Sirt1 may be a new therapeutic strategy for diabetic microangiopathy.
Methods and apparatus for extracting information from multi-channel measurement data are disclosed. In one arrangement, the measurement data is input to a set of trained first machine learning models, each channel to a different first machine learning model. Outputs provide respective sets of extracted feature maps, one set for each of the channels and each set comprising one extracted feature map for each of a plurality of convolution kernels. The outputs are combined and input to a trained second machine learning model, which provides a model prediction about the state of a subject. Interpretation information is generated that indicates relative strengths of contribution to the model prediction from different portions of the measurement data in each channel. The interpretation information for each channel is generated based on a weighted sum of the extracted feature maps output from the respective first machine learning model.
A dusting powder having fungicidal and bactericidal properties comprises a finely divided cation exchange resin having carboxy groups as the functional groups thereof, said resin being dispersed in a powder base.  The resin may be prepared by co-polymerizing maleic anhydride and styrene in the presence of a cross-linking agent such as divinylbenzene, trivinylbenzene, ethylene diacrylate or diallyl maleate, fumarate or itaconate, or by co-polymerizing acrylic or methacrylic acid and a polyunsaturated polymerizable substance such as diallyl maleate, fumarate, or itaconate, allyl acrylate, allyl methacrylate, diallyl ether, ethylene dimethacrylate or divinylbenzene.  The powder base may comprise talc, starch, kaolin, zinc oxide or titanium oxide.  Metallic soaps such as zinc or magnesium stearate or laurate may be added to promote good dispersion and adhesion. Wetting agents for example alkaryl sulphomates, octylphenoxy ethoxyethoxy-ethyl sodium sulphonate, methylene bis (alkylphenoxypolyethoxyethanol), and octylphenoxy polyethoxyethanols, emolients such as a fatty glyceride or lanolin, and humectants, for example glycerine, may be present. Other substances which may be present are sulphur, calomel, sulphanilamide, boric acid, salicylic acid, ammonium chloride, phenol, undecylenic acid, oxyquinoline sulphate, N-a  pyridyl-N-benzyl-N1,N1-dimethylethylene diamine streptomycin and tyrothrycin.  The resin may be used to hold small amounts of basic materials, for example local anaesthetics or antibiotics having a basic group, and may be partially converted to salt form, for example the copper or zinc salt.  The resin may be a mixed sulphonic-carboxylic ion exchange resin and in this case the sulphonic group may be in salt form, for example the sodium, calcium, magnesium, copper or zinc salt.
BACKGROUND: This report describes the authors' experience with 150 consecutive robotic pancreatoduodenectomies.
METHODS: The study enrolled 150 consecutive patients who underwent robotic pancreatoduodenectomy between 2018 and 2023. Pre- and intraoperative variables such as age, gender, indication, operation time, diagnosis, and tumor size were analyzed. The patients were divided into two groups. Group 1 comprised the first 75 patients, and group 2 comprised the last 75 cases. The median age of the patients was 62.4 years and did not differ between the two groups.
RESULTS: Morbidity was lower in group 2. The mortality rate was 0.7% at 30 days and 1.3% at 90 days, and there was no difference between the groups. There was a significant reduction (p < 0.05) in operative time, resection time, reconstruction time, and conversion to open surgery in group 2. Partial resection of the portal vein was performed in 17 patients and more common in group 2 (p < 0.01). The number of resected lymph nodes was higher in group 2. The indication for pancreatoduodenectomy did not differ between the two groups. There was no difference in tumor size or clinical characteristics of the patients.
CONCLUSIONS: The robotic platform is useful for pancreatoduodenectomy, facilitates adequate lymphadenectomy, and is helpful for digestive tract reconstruction after resection. Robotic pancreatoduodenectomy is safe and feasible for selected patients. It should be performed in specialized centers by surgeons experienced in open and minimally invasive pancreatic surgery.
The present invention relates to a pure traditional Chinese medicine honey pill for treating kidney diseases and preparation technique thereof, which provides a medicine preparation for treating kidney diseases and a preparation technique thereof. The medicine preparation is prepared from fifteen traditional Chinese medicines, such as milkvetch root, dodder seed, black alum, etc. The preparation method of the pure traditional Chinese medicine honey pill for treating kidney diseases comprises the four steps: mixing medicine powder; decocting the medicine powder into thick paste; stirring the thick paste into pills; sterilizing and subpackaging the pills. The pure traditional Chinese medicine honey pill has the advantages of scientific formula, simple and convenient preparation process and low cost, and has the functions of tonifying the kidney, promoting urination, supplying qi, securing the exterior, nourishing the liver, moistening the lung, warning the spleen, promoting digestion, benefiting blood, quieting heart spirit, eliminating blood stasis and regenerating new blood. Besides the pure traditional Chinese medicine honey pill has obvious treatment effects on protein urine, bloody urine, edema, etc. caused by acute and chronic nephritis, diabetes kidney diseases, hypertension kidney diseases, henoch-schonlein purpura nephritis and nephrotic syndromes.
Patients receive ALX148 IV over 1 hour once on days 1, 8, 15 and 22, or days 1 and 15, or day 1 depending on dose level. Patients also receive rituximab IV over 4-6 hours on days 1, 8, 15 and 22 of cycle 1, then on day 1 of cycles 2-6, and lenalidomide PO QD on days 1-21 of cycles 1-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients with vocal cord polyps commonly present with symptoms of hoarseness. Although rare, large polyps can cause shortness of breath and stridor and should be included in the differential for patients with airway obstruction. Dysphonia or hoarseness can be a symptom of underlying disease, such as head and neck cancer. This case illustrates the importance of prompt and accurate diagnosis in a patient with persistent symptoms and a history of smoking. Obtaining a laryngoscopy is crucial to appropriately evaluate the larynx. Proper visualization of the laryngeal structures will help direct patient care toward further diagnostic imaging and medical or surgical intervention if indicated.
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500).
Oxidative stress (OS) is a major mediator of secondary brain injury following intracerebral hemorrhage (ICH). Thus, antioxidant therapy is emerging as an attractive strategy to combat ICH. To achieve both reactive oxygen species (ROS) scavenging ability and on-demand drug release ability, we constructed a novel polydopamine (PDA)-coated diselenide-bridged mesoporous silica nanoparticle (DSeMSN) drug delivery system (PDA-DSeMSN). Edaravone (Eda) was blocked in the pores of DSeMSN by covering the pores with PDA as a gatekeeper. The drug maintained nearly "zero release" before reaching the lesion site, while in the ROS-enriched circumstances, the PDA shell went through degradation and the doped diselenide bonds broke up, triggering the disintegration of nanoparticles and leading to Eda release. Interestingly, the ROS-degradable property of the PDA shell and diselenide bond endowed the system with enhanced ROS-eliminating capacity. The synergistic effect of ROS-responsive drug delivery and ROS-scavenging PDA-DSeMSN showed efficient antioxidative and mitochondria protective performance without apparent toxicity in vitro. Importantly, PDA-DSeMSN@Eda through intravenous administration specifically accumulated in perihematomal sites and demonstrated robust neuroprotection in an ICH mouse model through antioxidative and antiapoptotic effects with high biological safety. Thus, the PDA-DSeMSN platform holds tremendous potential as an excellent carrier for on-demand delivery of drugs and provides a new and effective strategy for the clinical treatment of ICH.
Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4 ). Aged between 6 years and 70 years. Treated with Zinc.
The invention provides mRNA, which comprises mRNA encoding one, two, three or four proteins or fragments thereof from S protein, E protein, M protein and N protein of SARS-CoV-2 virus, the sequence of the mRNA encoding the S protein is shown as SEQ ID NO.18, SEQ ID NO.19 or SEQ ID NO. 20; the sequence of mRNA encoding E protein is shown as SEQ ID NO. 21; the sequence of mRNA encoding M protein is shown as SEQ ID NO. 22; the sequence of mRNA encoding the N protein is shown as SEQ ID NO. 23. Also provided are a liposome nanoparticle comprising the mRNA, an mRNA vaccine against a novel coronavirus, and the like. The mRNA of the present invention produces viral proteins at cellular levels with high efficiency or self-assembles into virus-like particles from the produced proteins. When the mRNA containing the invention is prepared into a vaccine, the safety is high, the effectiveness is good, non-neutralizing antibodies can not be generated, and the antibody dependence enhancing infection effect can not be generated.
PURPOSE OF REVIEW: The purpose of this review is to update the reader with recent advances and current opinion on the assessment and management of paediatric voice disorders.
RECENT FINDINGS: Access to advanced multidisciplinary paediatric voice clinics has increased over the last decade. Often the assessment is combined between speech therapy/pathology and ENT surgery. Vocal fold nodules remain the most prevalent diagnosis at a paediatric voice clinic, but significant diseases will also present, for example laryngeal papilloma. Recently, more consideration of the psychosocial aspect of voice disorders and evaluation of auditory processing disorders have shown how these can have a negative impact. There also appears to be a lack of parental and teacher awareness of paediatric voice disorders and their significance.
SUMMARY: We would recommend multiparametric assessment and analysis of all children with a voice disorder. Most paediatric voice conditions will respond to skilled voice therapy. However, the exact techniques and dosage requires further evaluation and research. Paediatric voice conditions are common and should not be dismissed, as they may represent significant disease, for example papilloma, vagal palsy or have a significant psychosocial impact on the child.